Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 5, 2025Neuro-OncologyOpen Access

P14.07.b Car T-Cell Therapy in Primary Central Nervous System Lymphomas: A Multicenter Retrospective Study From the Loc Network

View Full Paper
Ask AI
Bookmark
Share

Authors

FBFrançois BouilleMBMarine BaronRHRoch Houot

Discussion

Loading...

Member takes

Overview

Retrospective analysis indicates improved complete response rates in PCNSL patients treated with CAR T-cells, suggesting potential for expanded use.

Key Points

  • Complete response achieved in 58% of patients receiving CAR T-cell therapy, indicating significant efficacy.
  • Two-year progression-free survival rate of 44% suggests lasting benefits from CAR T-cell treatment in PCNSL.
  • Cytokine release syndrome occurred in 95% of patients, with most cases being manageable.
  • This large-scale retrospective study highlights the potential of CAR T-cells in a heavily pre-treated population.

Cite This Study

Bouille et al. (2025) studied this question.

synapsesocial.com/papers/68e24e6bd6d66a53c2473b2ehttps://doi.org/10.1093/neuonc/noaf193.468
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1P14.05.B CAR T-CELL THERAPY DOES NOT LEAD TO MEDIUM-TERM NEUROCOGNITIVE DETERIORATION IN PATIENTS WITH CENTRAL NERVOUS SYSTEM LYMPHOMAS. A LOC NETWORK STUDY2025
  2. 2Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  3. 3CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry2025
  4. 4Tandem combination of <scp>ASCT</scp> and <scp>CAR</scp> T‐cell therapy in highly refractory <scp>CNS</scp> lymphomas2025
  5. 5Anti-CD19 CAR-T cells for Mantle Cell Lymphoma with central nervous system involvement: A study of the french descart registry.2025